Skip to main content
Celularity Inc logo

Celularity Inc — Investor Relations & Filings

Ticker · CELU ISIN · US1511901050 US Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2026-06-03 Board/Management Inform…
Country US United States of America
Listing US CELU

About Celularity Inc

https://celularity.com/

Celularity Inc. is a clinical and commercial-stage biotechnology company specializing in cellular and regenerative medicine. The company develops and commercializes therapies derived from the postpartum human placenta. Its core focus is on creating off-the-shelf, allogeneic cell therapies, including genetically modified and unmodified Natural Killer (NK) cells, CAR T-cells, and mesenchymal-like adherent stromal cells (MLASCs). These therapeutic programs target a range of conditions, including cancer, immune disorders, and aging-related degenerative diseases. In addition to its clinical pipeline, Celularity markets a suite of commercial placenta-derived biomaterial products. The company leverages the unique biological properties of the placenta to develop accessible treatments for significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 91% confidence The document is a Current Report on Form 8-K filed with the SEC. The key items disclosed are Item 5.02 (Departure and appointment of certain officers/directors) and Item 7.01 (Regulation FD disclosure), including the appointment of a new Chief Commercial Officer. This is clearly an announcement of changes in senior management rather than a full financial report, earnings release, or other filing. Therefore, it fits the “Board/Management Information” category.
2026-06-03 English
8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K (Current Report) filed with the SEC, disclosing the entry into a material definitive agreement (a settlement agreement) and creation of a financial obligation. It is a regulatory filing under the Exchange Act rather than a full financial report, earnings release, or any other specific category. Therefore, it falls under Regulatory Filings (RNS).
2026-05-28 English
8-K - Celularity Inc (0001752828) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about an amendment to a material definitive agreement, creation of a direct financial obligation, material modifications to rights of security holders, departure of directors or officers, and other events such as a press release. It does not contain full financial statements or comprehensive financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It also is not a transcript, proxy statement, or remuneration report. The document is a regulatory filing reporting significant corporate events and changes, consistent with the definition of Regulatory Filings (RNS). The length is over 10,000 characters and contains detailed disclosures, but it is not a full financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-04-21 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-11 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is under Item 5.02, which details the departure, election, or appointment of directors or certain officers, specifically an amendment to the employment agreement of a senior executive officer. There are no financial statements or detailed financial data present, and the document is relatively short (4319 characters). This matches the description of Board/Management Information filings, which announce changes in the company's board or senior management. Therefore, the correct classification is MANG (Board/Management Information).
2026-01-21 English
4/A
Director's Dealing
2026-01-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.